Evista will be used more to reduce the risk of breast cancer

October 2007

Evista will be used more to reduce the risk of breast cancer.

The FDA just approved this use for postmenopausal women with osteoporosis...or those at high risk for breast cancer.

Many already use Evista (raloxifene) as an alternative to tamoxifen to reduce breast cancer risk.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote